stockportfolio.pro
Elanco Animal Health Incorporated (ELAN)
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Elanco Animal Health Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.91B | $2.89B | $3.07B | $3.07B | $3.27B | $4.76B | $4.42B | $4.42B | $4.44B | $4.71B |
| Gross profit | $1.50B | $1.40B | $1.49B | $1.60B | $1.61B | $2.63B | $2.50B | $2.49B | $2.44B | $2.59B |
| Net income | $-47.90M | $-310.70M | $86.50M | $68.00M | $-574.00M | $-483.00M | $-74.00M | $-1.23B | $338.00M | $-232.00M |
| Net margin | -1.6% | -10.8% | 2.8% | 2.2% | -17.5% | -10.1% | -1.7% | -27.9% | 7.6% | -4.9% |
Source: Elanco Animal Health Incorporated SEC filings (10-K).
Explore 10 years of Elanco Animal Health Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ELAN in your portfolio →
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Elanco Animal Health Incorporated — frequently asked questions
What is Elanco Animal Health Incorporated's revenue?
Elanco Animal Health Incorporated (ELAN) reported revenue of $4.71B for fiscal year 2025, up 6.2% from the prior year, according to its SEC filings.
Is Elanco Animal Health Incorporated profitable?
No — ELAN reported a net loss of $-232.00M in fiscal 2025.
What is ELAN's P/E ratio?
Elanco Animal Health Incorporated trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Elanco Animal Health Incorporated growing?
ELAN's revenue grew at roughly 7.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Elanco Animal Health Incorporated's official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.